Benefits
Provitamin A activity
Beta-carotene is the most abundant provitamin A carotenoid. Approximately 12 μg of dietary β-carotene is required to provide 1 μg retinol activity equivalent (RAE). For populations with vitamin A deficiency (especially in low-income countries), β-carotene-rich foods are an important source of vitamin A for vision, immunity, growth, and reproduction.
Antioxidant and free radical scavenging
Beta-carotene quenches singlet oxygen and scavenges peroxyl radicals. Particularly important in the eye (macular protection), skin (UV protection), and tissues exposed to high oxidative stress. Mixed-carotenoid intake from food associates with reduced oxidative stress markers in observational studies.
Eye health (with cofactor formula)
AREDS Report No. 8 demonstrated that high-dose antioxidants (15 mg β-carotene + 500 mg vitamin C + 400 IU vitamin E) plus zinc reduced the 5-year risk of progression to advanced age-related macular degeneration by ~25% and reduced visual acuity loss by ~19% in patients with intermediate or advanced AMD. NOTE: AREDS2 subsequently removed β-carotene because of smoker risk and replaced it with lutein/zeaxanthin.
Skin photoprotection
Long-term oral β-carotene at 30-60 mg/day modestly reduces erythema response to UV exposure (about 0.5 minimal erythemal dose protection) — equivalent to a low single-digit SPF. Effect emerges only after 10+ weeks of supplementation; not a substitute for sunscreen.
Mechanism of action
Conversion to retinol (vitamin A)
In the intestinal mucosa, β-carotene-15,15'-monooxygenase (BCMO1) cleaves β-carotene at the central 15,15' double bond to yield two molecules of retinal, which are then reduced to retinol. Conversion is regulated by vitamin A status — efficiency decreases when vitamin A stores are adequate. Genetic polymorphisms in BCMO1 cause significant variation in conversion efficiency between individuals.
Singlet oxygen quenching
The conjugated polyene structure of β-carotene allows extremely efficient quenching of singlet oxygen — among the most reactive species generated by UV exposure and metabolism. Each carotenoid molecule can quench up to 1,000 singlet oxygen molecules before being degraded.
Pro-oxidant activity at high concentrations and high oxygen tension
Critical: at the elevated oxygen tensions found in lung tissue, particularly in smokers exposed to cigarette smoke pro-oxidants, β-carotene can become a pro-oxidant rather than antioxidant. Eccentric cleavage produces apo-carotenals and other reactive metabolites that damage DNA, alter retinoid signaling, and may explain the increased lung cancer incidence observed in supplementation trials.
Clinical trials
Randomized, double-blind, placebo-controlled, 2×2 factorial design (Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study, N Engl J Med 330(15):1029-1035). Conducted in southwestern Finland 1985-1993.
29,133 male smokers aged 50-69 years from southwestern Finland. Randomized to one of four regimens: α-tocopherol 50 mg/day alone, β-carotene 20 mg/day alone, both, or placebo. Median follow-up 6.1 years.
Among 876 new lung cancer cases, β-carotene supplementation was associated with an 18% INCREASE in lung cancer incidence (RR 1.18, 95% CI 1.03-1.36) and 8% increase in total mortality compared to those not receiving β-carotene. The unexpected harmful finding was opposite to what observational studies had predicted. Study transformed clinical understanding of antioxidant supplementation in high-risk populations.
6-year post-intervention follow-up of randomized, double-blind, placebo-controlled trial (Goodman, Thornquist, Balmes, Cullen, Meyskens, Omenn, Valanis, J Natl Cancer Inst 96(23):1743-1750).
18,314 men and women at high risk for lung cancer (heavy smokers or asbestos-exposed workers) randomly assigned to daily β-carotene 30 mg + retinyl palmitate 25,000 IU vs placebo. Trial halted in 1996 ahead of schedule due to harm signal.
Active treatment group had 28% INCREASED lung cancer incidence and 17% increased death rate vs placebo at trial halt. After 6 years of post-intervention follow-up, the increased lung cancer incidence persisted but lost statistical significance. Subgroup analysis suggested excess lung cancer risk was concentrated in females and excess cardiovascular mortality in females and former smokers. Combined with ATBC, established that high-dose β-carotene supplementation is harmful in smokers.
Randomized, double-blind, placebo-controlled trial (Hennekens, Buring, Manson, Stampfer, Rosner, Cook, Belanger, LaMotte, Gaziano, Ridker, Willett, N Engl J Med 334(18):1145-1149).
22,071 male U.S. physicians aged 40-84. Randomized to β-carotene 50 mg every other day vs placebo. Median follow-up 12 years. 11% current smokers and 39% former smokers at baseline.
No significant effect on cancer incidence (RR 0.98, 95% CI 0.91-1.06), cardiovascular events (RR 1.0), or total mortality. Provided evidence that in a population WITHOUT heavy smoking exposure, long-term β-carotene supplementation neither helps nor harms. The contrast with ATBC and CARET highlighted the smoker-specific harm.
Multicenter, randomized, double-masked, placebo-controlled clinical trial (AREDS Research, Arch Ophthalmol 119(10):1417-36).
3,640 participants aged 55-80 with various stages of age-related macular degeneration. Randomized to: (1) antioxidants (vit C 500 mg + vit E 400 IU + β-carotene 15 mg); (2) zinc (80 mg + Cu 2 mg); (3) antioxidants + zinc; (4) placebo.
Antioxidants + zinc combination reduced 5-year risk of progression to advanced AMD by ~25% (OR 0.72, 99% CI 0.52-0.98) and risk of vision loss ≥15 letters by ~19% (OR 0.73, 99% CI 0.54-0.99) in participants with intermediate AMD or advanced AMD in one eye. AREDS2 subsequently demonstrated equivalent benefit when β-carotene was replaced with lutein/zeaxanthin, eliminating smoker risk.